Company Profile
An Industry Leader
UniPharma is recognized as a leading enterprise with a comprehensive organizational structure and a team of highly skilled professionals. Our operations span-new product evaluation, market analysis, business development, international branches, import/export, regulatory affairs, clinical research, marketing, sales, finance, warehousing and logistics management, auditing, and legal affairs. This robust infrastructure enables us to be one of the few pharmacy in Taiwan capable of offering vertically integrated core competencies in R&D, clinical trials, and commercial operations.
As a comprehensive R&D-driven company, we maintains full control over its products and is continuously engaged in innovative product development. We collaborate with a team of scientific advisors and research institutions, applying the latest technologies to enhance Onko-Sure DR-70, with the goal of developing a second-generation product. In parallel, we are planning the development of a third-generation combination assay that integrates Onko-Sure DR-70 with additional tumor markers. These advanced innovations will be protected under exclusive patents, ensuring proprietary rights and market exclusivity.
Message from the Chairman
A Pioneer in Industry Innovation
UniPharma is a trailblazer in the healthcare industry, backed by a comprehensive organizational structure and a team of highly qualified professionals. Our capabilities encompass new product evaluation, market analysis, business development, international operations, import/export management, regulatory affairs, clinical research, marketing, sales, finance, warehousing and logistics, auditing, and legal affairs. This breadth of expertise makes us one of the few companies in Taiwan capable of delivering vertically integrated services across R&D, clinical trials, and commercial execution.
Transitioning from a traditional pharmaceutical distributor, UniPharma is now evolving into a global brand developer, extending beyond national borders and shifting from a focus solely on treatment to one that also includes disease diagnostics. As a comprehensive R&D-driven enterprise, we maintain full control over our product pipeline and are committed to continuous innovation.
Through collaborations with leading scientific advisors and research institutions, we are leveraging advanced technologies to enhance Onko-Sure DR-70, aiming to develop a next-generation version with improved performance. Simultaneously, we are planning a third-generation combo assay, combining Onko-Sure DR-70 with additional tumor markers. These cutting-edge diagnostic tools will be protected under exclusive patents, securing proprietary rights and market exclusivity.
Looking ahead, UniPharma will continue to invest in medical research and development, including the establishment of a centralized laboratory to accelerate the commercialization of cancer diagnostics and personalized medicine. Guided by our five core values—Professionalism, Passion, Integrity, Compassion, and Responsibility—we remain dedicated to advancing innovation, expanding our global reach, and giving back to society through meaningful medical progress. Achieving our ultimate corporate vision remains our unwavering goal.
Jen Chen 陳正

Degree
– Ph.D., Institute of Chemistry, University of Rochester, USA
– B.S. in Chemistry, Tsinghua University, Taiwan
Experienced
– CIBA-GEIGY Corporation Program Facilitator
– General Manager of Genovate Biotechnology
– Chairman of the Board of Genovate Biotechnology
– Vice President of Asia- Pacific Area Genelabs Technologies, Inc.









